Phaseline

Companies › Gilva Therapeutics

Gilva Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GV-100–Phase 1ADPKD (Autosomal Dominant Polycystic Kidney Disease)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07788014GV-100Phase 1ADPKD (Autosomal Dominant Polycystic Kidney Disease)GenitourinaryMar 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.